Evidence map›Paper›PMID 38238048›Full record

ArticleBMJ open2024

Randomised placebo-controlled trial of antenatal corticosteroids for planned birth in twins (STOPPIT-3): study protocol.

Sarah Murray, Jessica Thompson, Rosie C Townsend, Manuela Deidda, Kathleen Anne Boyd, Jane E Norman, John Norrie, James P Boardman, Karen Luyt, Asma Khalil and 7 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sarah Murray *Centre for Reproductive Health, The University of Edinburgh, Edinburgh, UK sarah.murray@ed.ac.uk.ORCID 0000-0002-2344-6852
Jessica Thompson *Centre for Reproductive Health, The University of Edinburgh, Edinburgh, UK.
Rosie C TownsendCentre for Reproductive Health, The University of Edinburgh, Edinburgh, UK.
Manuela DeiddaHealth Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.ORCID 0000-0002-0921-6970
Kathleen Anne BoydHealth Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.ORCID 0000-0002-9764-0113
Jane E NormanUniversity of Nottingham Executive Office, University of Nottingham, Nottingham, UK.
John NorrieEdinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-9823-9252
James P BoardmanCentre for Reproductive Health, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-3904-8960
Karen LuytBristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0002-9806-1092
Asma KhalilMolecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
Debra BickWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-8557-7276
Keith ReedCEO, Parent Infant Foundation, London, UK.
Jane DentonCo lead Elizabeth Bryan Multiple Births Centre, Imperial College London, London, UK.
Natasha FenwickResearch and Resources Officer, Twins Trust, London, UK.
Catriona KeerieUniversity of Edinburgh College of Medicine and Veterinary Medicine, Edinburgh, UK.
Rebecca ReynoldsCentre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UK.
Sarah Jane StockCentre for Medical Informatics, The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK.ORCID 0000-0003-4308-856X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of the STOPPIT-3 study is to determine the clinical and cost effectiveness of antenatal corticosteroids (ACS) prior to planned birth of twins in a multicentre placebo-controlled trial with internal pilot. METHODS AND ANALYSIS: This study will comprise a multicentre, double-blinded, randomised, placebo-controlled trial in at least 50 UK obstetric units. The target population is 1552 women with a twin pregnancy and a planned birth between 35 and 38+6 weeks' gestation recruited from antenatal clinics. Women will be randomised to Dexamethasone Phosphate (24 mg) or saline administered via two intramuscular injections 24 hours apart, 24-120 hours prior to scheduled birth. OUTCOMES: The primary outcome is need for respiratory support within 72 hours of birth. Secondary and safety outcomes will be included. Cognitive and language development at age 2 years will be assessed in a subset of participants using the Parent report of Children's Abilities-Revised questionnaire. We will also determine the cost effectiveness of the treatment with ACS compared with placebo. ETHICS AND DISSEMINATION: STOPPIT-3 has been funded and approved by the National Institute of Healthcare Research. It has been approved by the West Midlands Research Ethics Committee (22/WM/0018). The results will be disseminated via publication in peer-reviewed journals and conference presentation and will also be communicated to the public via links with charity partners and social media. TRIAL SPONSOR: The University of Edinburgh and Lothian Health Board ACCORD, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ. TRIAL REGISTRATION NUMBER: ISRCTN59959611.

Indexed as

Adrenal Cortex HormonesPregnancy, TwinChildChild, PreschoolFemaleFranceGestational AgeHumansMulticenter Studies as TopicPregnancyRandomized Controlled Trials as TopicTwinsAdrenal Cortex HormonesFetal medicineNEONATOLOGYOBSTETRICS

Identifiers

PMID38238048
PMCPMC10806667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.